HCC and its microenvironment

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1433-1437

  Carr, Brian I ^a   Guerra, Vito ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

ALKP; Cirrhosis; GGTP; HCC; Portal vein thrombosis; Size; Survival

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HOST FACTOR; PROTHROMBIN;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT;

EID: 84885765193     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121028     Document Type: Article

References (40)

1. Vernook, AP, Papandreou C, Furuse J, de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15(Suppl 4):5-13.
2. Sherman M: Hepatocellular carcinoma: New and emerging risks. Digestive and Liver Dis 2010; 42S:S215-S222.
3. Wild CP, Gong YY: Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31:71-82.
4. Yu SZ, Chen G: Blue-green algae toxins and liver cancer. China J Cancer Res 1994; 6:9-17.
5. Kew MC: Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23:405-440.
6. Pradella P, Bonetto S, Turchetto S, et al.: Platelet production and destruction in liver cirrhosis. J Hepatol 2011; 54:894-900.
7. Lu SN, Wang JH, Liu SL, et al.: Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107:2212-2122.
8. Lu SN, Wang JH, Chen PF, et al.: Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev 2008; 17:1813-1821.
9. Kumada T, Toyoda H, Kiriyama S, et al.: Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011; 46:536-544.
10. Kumada T, Toyoda H, Kiriyama S, et al.: Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 2010; 82:539-545.
11. Kawamura Y, Arase Y, Ikeda K, et al.: Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107:253-261.
12. Montano-Loza AJ, Carpenter HA, Czaja AJ: Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103:1944-1951.
13. Lok AS, Seeff LB, Morgan TR, et al.; HALT-C Trial Group: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138-148.
14. Velazquez RF, Rodriguez M, Navascues CA, et al.: Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520-527.
15. Carr BI, Guerra V, Pancoska P: Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 2012; 83:339-345.
16. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P: Small hepatocellular carcinomas and thrombocytopenia. Oncology 2012; 83:331-338.
17. Nzeako UC, Goodman ZD, Ishak KG: Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinic-histopathologic study of 804 North American patients. Am J Clin Path 1996; 105:65-75.
18. Okuda K, Nakashima T, Kojiro M, et al.: Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989; 97:140-146.
19. Trevisani F, Frigerio M, Santi V, et al.: Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig. Liver Dis 2010; 42:341-347.
20. Truant S, Boleslawsky E, Duhamel A, et al.: Tumor size of hepatocellular carcinoma in noncirrhotic liver: A controversial predictive factor for outcome after resection. Eur J Surg Oncol 2012; 38(12):1189-1196.
21. Okuda K, Ohtsuki T, Obata H, et al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56:918-928.
22. Stone RL, Nick AM, McNeish IA, et al.: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610-618.
23. Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20:576-590.
24. Buergy D, Wenz F, Graden C, Brockmann MA: Tumor-platelet interactions in solid tumors. Int J Cancer 2012; 130:2747-2760.
25. Cho MS, Bottsford-Miller J, Vasquez HG, et al.: Platelets increase the proliferation of ovarian cancer cells Blood 2012; 120(24):4869-4872.
26. Zhou J, Tang YZ, Fan J, et al.: Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 2000; 126:57-61.
27. Gotzmann J, Fischer AN, Zoler M, et al.: A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 2006; 25:3170-3185.
28. Stock P, Monga D, Tan X, et al.: Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6:1932-1941.
29. Maass T, Thieringer FR, Mann A, et al.: Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer 2011; 128:1259-1268.
30. Okada H, Honda M, Campbell JS, et al.: Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012; 72(17):4459-4471.
31. Campbell JS, Hughes SD, Gilbertson DG, et al.: Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102:3389-3394.
32. Soll C, Jang JH, Riener MD, et al.: Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010; 51:1244-1254.
33. Lesurtel M, Clavien P-A: Serotonin: A key molecule in acute and chronic liver injury. Clin Res Hepatol Gastroenterol 2012; 36(4):319-322.
34. Dunigan JT, Carr BI, Steel JL: Posttraumatic growth, immunity and survival in patients with hepatoma. Dig Dis Sci 2007; 52(9):2452-2459.
35. Steel JL, Geller DA, Gamblin TC, Olek MC, Carr BI: Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25:2397-2405.
36. Ripoli C, Groszmann RJ, Garcla-Tsao G, et al.: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50:923-928.
37. Jung KS, Kim SU, Ahn SH, et al.: Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53:885-894.
38. Yang ZF, Ho DW, Lau CK, et al.: Platelet activation during tumor development, the potential role of BDNF-TrkB autocrine loop. Biochem Biophys Res Commun 2006; 346:981-985.
39. Carr BI, Pancoska P, Branch RA: Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol 2010; 25(9):1543-1549.
40. Leonardi GC, Candido S, Cervello M, et al.: The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012; 40:1733-1747.